Semaglutide Phase 3 Trial in Type 2 Diabetes Reaches Primary Completion

A Phase 3 clinical trial (NCT06716216) evaluating BGM0504 against semaglutide in participants with Type 2 Diabetes Mellitus reached its primary completion on March 20, 2026. This study, conducted in China, aims to assess the efficacy and safety of BGM0504 as an add-on therapy to metformin and/or sulfonylureas, with semaglutide serving as a comparator.

Background

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, a class of drugs widely used in the management of Type 2 Diabetes Mellitus (T2DM). It is known for its ability to improve glycemic control and has been approved in various formulations (e.g., Wegovy, Ozempic, Rybelsus) for T2DM and weight management. The current trial uses semaglutide as an active comparator to evaluate a new investigational drug, BGM0504, in the context of T2DM treatment.

Trial design

The study, titled "A Study of BGM0504 in Participants with Type 2 Diabetes" (NCT06716216), is a Phase 3 trial. It has an estimated enrollment of 537 participants, all diagnosed with Type 2 Diabetes Mellitus. The trial is being conducted in China. Participants receive either 5 mg BGM0504 administered subcutaneously, 10 mg BGM0504 administered subcutaneously, or semaglutide administered subcutaneously. The primary objective is to evaluate the efficacy and safety of BGM0504 versus semaglutide when added to existing metformin and/or sulfonylurea regimens.

What this means

The primary completion of this Phase 3 trial signifies that the final data collection for the primary outcome measures has concluded. While specific results are not yet available, this milestone indicates progress towards understanding the efficacy and safety profile of BGM0504 in comparison to an established treatment like semaglutide for Type 2 Diabetes Mellitus. Clinicians and researchers will be awaiting the detailed results to assess the potential role of BGM0504 in the evolving landscape of T2DM management, particularly as an add-on therapy in a Chinese patient population.

Source

Information regarding the primary completion of trial NCT06716216 was obtained from ClinicalTrials.gov, a public database of clinical studies. The event, "Phase 3 primary completion: NCT06716216," was recorded with a date of March 20, 2026 on clinicaltrials.gov.